The Effects of Pettocytineib on Adverse Events of Special Interest

It examines upatocytineib versus adelimumab and methotryxit monotherapy to see whether adverse events of special interest occur more frequently among patients with elevated risk of CD events. Patients received in select compare with pettocytine 15 milligrams, once a day with or without conventional synthetic demars orAdelimumab 40 milligrams every other week with concomitant methotryxate. Three populations were assessed for adverse events of interest. The overall population, patients with higher CV risks from the overall population and patients with higherCV risks specifically from select compare.